Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy

Transplantation and Cellular Therapy(2023)10.1016/j.jtct.2023.04.001Source: DataRank Database

Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy is a research paper published in Transplantation and Cellular Therapy (2023). On theSindex it has a DataRank of 3.7. It has been cited 144 times, with 140 citing works in its 1-hop citation network.

N/A

3.7DataRank · unranked

Scored on demand from live citation data

Open Access144 citations · 140 citing works in its network

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 16.37)OA: greenTopics (37)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 20%Citation Network 80%

Base Score Contribution

0.747

From this paper's citation signal

Citation Network Contribution

3.0

From 107 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 140 citers.

Cyclophosphamide Abrogates Immune Effector Cell‐Associated Neurotoxicity Syndrome Associated With CAR‐T Cell Therapy
American Journal of Hematology20255 citations6 referencesContributes 0.299
Involvement of the hospital pharmacist in securing the chimeric antigen receptor (CAR)-T cell circuit
European Journal of Hospital Pharmacy20252 citations5 referencesContributes 0.220
A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma
Blood Advances202345 citations21 referencesContributes 0.182
Need for standardization of cytokine profiling in CAR T cell therapy
Molecular Therapy202413 citations23 referencesContributes 0.115
Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis
Cancer Research Communications20246 citations21 referencesContributes 0.093

Authors (24)

Emily C. Liang ORCID,Qian Wu ORCID,Jenna Voutsinas ORCID,Pere Barba ORCID,Gloria Iacoboni ORCID

Live enrichment

PubMed:37031746 PMC:PMC10330552 OpenAlex:https://openalex.org/W4362693419

National Cancer Institute

Grant: P30 CA015704-45

NCI NIH HHS

Grant: P30 CA015704

NCI NIH HHS

Grant: K12 CA076930

National Institutes of Health

FWCI

16.37

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

greenLicense: http://creativecommons.org/licenses/by-nc-nd/4.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10330552/pdf/nihms-1903039.pdf

publisherhttps://api.elsevier.com/content/article/PII:S2666636723012332?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666636723012332?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10330552

Fields of Study

CAR-T cell therapy researchAdvancements in Semiconductor Devices and Circuit DesignNanowire Synthesis and ApplicationsHumansReceptors, Chimeric AntigenInterleukin 1 Receptor Antagonist ProteinCytokine Release SyndromeProspective StudiesRetrospective StudiesPlasma CellsFerritinsCell- and Tissue-Based TherapyNeurotoxicity Syndromes

MeSH Terms

Receptors, Chimeric AntigenCytokine Release SyndromeFerritinsHumansPlasma CellsProspective StudiesRetrospective StudiesNeurotoxicity SyndromesInterleukin 1 Receptor Antagonist ProteinCell- and Tissue-Based Therapy

Keywords

AnakinraMedicineCytokine release syndromeChimeric antigen receptorInternal medicineDiscontinuationImmunologyDiseaseImmunotherapyCancerToxicityCrsIcansCar-t Cell Therapy

Sustainable Development Goals

SDG 0: Good health and well-being